Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X842 in Reflux Esophagitis
NCT07079540Phase 3Completed
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd.
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linaprazan glurate in reflux esophagitis, sponsored by Jiangsu Sinorda Biomedicine Co., Ltd.. Started Jun 2021; status: completed.
02
Drugs
linaprazan glurate
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT07079540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07079540.